Sanofi (SNY) said Tuesday that phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints, compared with placebo.

A phase 2b study of adult patients with moderate-to-severe asthma showed a "statistically significant and clinically meaningful reduction" in exacerbations and improvement in lung function, Sanofi said.

A phase 2a proof-of-concept study met its primary endpoint of change in nasal polyp score from baseline and met its key secondary endpoints of change in patient reported nasal congestion/obstruction score and change in Lund-Mackay Computed Tomography score, all compared with placebo at week 24, according to the company.

Lunsekimig was "well tolerated, with an acceptable safety profile" in both studies, Sanofi said.

A separate exploratory phase 2b study evaluating lunsekimig in moderate-to-severe atopic dermatitis didn't meet its primary endpoint, though there were certain improvements in the key secondary endpoints, according to the company.

Sanofi shares were up 1% in premarket activity.